A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

Clinical trial NCT07182682 · RECRUITING

Trial details

NCT number: NCT07182682
Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2025-12-01
Primary completion: 2029-09-01
Enrollment: 360

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.